Register now to learn more about GIAPREZA

Receive the latest information and updates about GIAPREZA.
*Required field.
Enter a valid first name.
Enter a valid last name.
Enter a valid zip code.
Select a specialty.
Submit
We're sorry, an error has occurred while submitting the form.

Thank you for registering

Important Safety Information


Indication

GIAPREZA™ (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications

None.

Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled ATHOS-3 study. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism prophylaxis.

Adverse Reactions

The most common adverse reactions reported in greater than 10% in GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions

Angiotensin converting enzyme inhibitors may increase response to GIAPREZA.
Angiotensin II receptor blockers may reduce response to GIAPREZA.

To report SUSPECTED ADVERSE REACTIONS, contact La Jolla Pharmaceutical Company at 1-800-651-3861 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional Important Safety Information, please see the full Prescribing Information.

Reference:   1. GIAPREZA™ (angiotensin II) [package insert]. San Diego, CA: La Jolla Pharmaceutical Company; 2017.

Important Safety Information

Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the